| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 16, 2012- Full-year revenue from continuing operations increased $418 million, or 15%, to a record $3.2 billion.
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012. (Logo:...
-
Aug 15, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on September...
-
Aug 9, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Aug 8, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Aug 2, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its fourth quarter and fiscal year 2012 on Thursday,...
-
Jun 27, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Jun 11, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Clobetasol propionate...
-
Jun 8, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer Judy Brown will present at the...
-
Jun 6, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 30, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval to Tris Pharma for its...